The study captures in detail how the functions, locations, and characteristics of various immune cells sculpt the tumor microenvironment (TME) to thwart immune attack, support cancer cell survival and drive tumor progression.
The authors write that if it uses a similar method to SARS or MERS to infect the body it probably compromises the body’s ability to fight the virus by preventing interferon 1—one of the first proteins produced by the immune system to fight viruses—from functioning properly.
The results reportedly are the first in any human neurovascular disease and have implications both for treating the disease and in examining other neurovascular diseases that could be affected by a person’s gut microbiome.
The reported study data have led to the formation of a new start-up brain cancer immunotherapy company, Empirica Therapeutics, which aims to start clinical trials of the CD133-targeting CAR-T-cell therapy in recurrent glioblastoma patients by 2022.
A growing number of diagnostics developers have set out to address the challenge of meeting the nation’s need for more COVID-19 tests. Here we profile five companies that have answered that challenge by working to bring new assays, with new technologies, to patients.
GNS Healthcare and partners said the identification of PHF19 could lead to improvements in how diagnostics developers target the transcription factor through single gene tests—as well as how researchers design clinical trials, and how oncologists make decisions on treating patients with newly diagnosed multiple myeloma.
Combination of Genentech’s Actemra, Gilead’s Remdesivir Enters Phase III Trial for Treatment of Severe...
The global randomized, double-blind, placebo-controlled Phase III trial—to be called REMDACTA—will compare the safety and efficacy of Actemra plus remdesivir to placebo plus remdesivir in severe COVID-19 patients receiving standard of care.
The research “revealed epigenetic alterations to the MEC regulatory landscape that enable reactivation of pregnancy-induced programs in response to pregnancy hormones,” the investigators said, which influenced the development of premalignant lesions in response to oncogene overexpression.
While miRNAs can regulate many genes, they have been shown to have a strong impact on cancer development and on processes such as cancer drug resistance.
The app leverages large cancer data repositories to calculate mortality risks associated with immediate compared with delayed treatment and also takes into account age, cancer type, treatment plan, and presence of other comorbidities.